Celularity welcomes CMS action on Medicare LCD for skin substitutes products

Celularity (CELU) welcomes action by the Centers for Medicare & Medicaid Services, or CMS, to revise to January 1, 2026, the effective date of the Medicare Local Coverage Determination, or LCD, titled “Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers” first published in November 2024. “We applaud the leadership of CMS Administrator Dr. Mehmet Oz to ensure continued access to these critical wound care products for Medicare patients who suffer from diabetic foot ulcers and venous leg ulcers,” said Dr. Robert J. Hariri, Celularity Chairman and CEO. “CMS’ action averted a looming healthcare crisis for diabetic Americans, for whom access to treatment with skin substitutes can be critical to avoiding serious complications like sepsis, amputations, and even premature death. We fully endorse payment system reform, which this action ensures can now occur on an inclusive, thorough basis that yields lower cost of care without compromising Medicare patient access.”